Solid Tumor Profiling for Targeted
and Immunotherapy Therapy Selection

OncoGxOne™ is a comprehensive molecular test for detecting driver mutations and immunotherapy biomarkers in solid tumors

f38b8126-7841-4516-8aa5-0b3d75da4830 OncoGxOne™ - Solid Tumor Profiling
fa23de79-90fe-4693-9eab-0eecbe360b27 OncoGxOne™ - Solid Tumor Profiling

Solid Tumor Profiling for Targeted
and Immunotherapy Therapy Selection

OncoGxOne™ is a comprehensive molecular test for detecting driver mutations and immunotherapy biomarkers in solid tumors

f38b8126-7841-4516-8aa5-0b3d75da4830 OncoGxOne™ - Solid Tumor Profiling
fa23de79-90fe-4693-9eab-0eecbe360b27 OncoGxOne™ - Solid Tumor Profiling
OncoGxOne OncoGxOne™ - Solid Tumor Profiling

OncoGxOne™ is a comprehensive 364 gene Next Generation Sequencing assay for profiling all solid tumor types. Input includes both DNA and RNA for optimal fusion detection.

Turnaround time:Depth of coverage:
7-10 business daysAvg. 250-500X (min. 100X)

Somatic Mutation Detection

Somatic-Mutation-Detection2 OncoGxOne™ - Solid Tumor Profiling

Immunotherapy Biomarkers

Immune checkpoint inhibitors have become popular therapeutics due to their ability to facilitate the body’s immune system to target and kill cancer cells. OncoGxOne™ measures three types of biomarkers that can help determine if a tumor is likely to respond to these types of therapies.

Immunotherapy-Biomarkers OncoGxOne™ - Solid Tumor Profiling

Actionable Results

Picture3 OncoGxOne™ - Solid Tumor Profiling
467f352b-1f43-46e0-9020-1accb1477e86 OncoGxOne™ - Solid Tumor Profiling

Immunotherapy Results for Checkpoint Inhibitors

OncoGxOne™ includes fragment analysis of five well-validated satellite regions recognized by national guidelines. MSI is the result of a deficient mismatch repair system. Tumors with MSI-High tend to have an increased neoantigen burden, an indication that the patient may benefit from cancer immunotherapy. If two of more sites are detected as unstable the sample will be classified as MSI-High. 

TMB is a quantitative and genomic-based biomarker for cancer immunotherapy selection. OncoGxOne™ measures the total number of somatic mutations per mega base (MB), classifying TMB as:

TMB-High with mutations > 10 per MB
TMB-Low with mutations lessthanequalto OncoGxOne™ - Solid Tumor Profiling 10 per MB

Tumors with TMB-High tend to have an increased neoantigen burden, an indication that the patient may benefit from cancer immunotherapy.

Not all tumors determined to be MSI-High or TMB-High respond to tumor checkpoint inhibitors. It has been hypothesized that tumors with high HLA heterozygosity will have a strong antitumor immune response. OncoGxOne™ genotypes 14 HLA alleles to determine both homozygosity and heterozygosity which can be used to further stratify potential responders to cancer immunotherapy.

OncoGxOne™ compliments Admera Health’s suite of Next Generation Sequencing tests, spanning the continuum of cancer patient care.

Admera-Health-Suite-of-NGS-Tests OncoGxOne™ - Solid Tumor Profiling
PGxOne™-Plus-Logo OncoGxOne™ - Solid Tumor Profiling

A comprehensive pharmacogenomics test to aid in therapeutic decisions, including cancer treatments and supportive care.

Learn more
LiquidGx_Logo OncoGxOne™ - Solid Tumor Profiling

A non-invasive cancer test for selecting targeted therapies for solid tumors and resistance monitoring.

Learn more